1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Clindamycin Phosphate Topical Lotion
Trade Name: CLEOCIN T; DALACIN T; DALACIN C
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification
Skin Sensitization: Category 1

Label Elements

Signal Word: Warning
Precautionary Statements:
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P272 - Contaminated work clothing must not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental instructions on the administration of antidotes on this label)
P363 - Wash contaminated clothing before reuse
P501 - Dispose of contents/container in accordance with all local and national regulations
Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous</th>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Glycerin, USP</td>
<td>56-81-5</td>
<td>200-289-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Glycerl stearate</td>
<td>123-94-4</td>
<td>204-664-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Clindamycin Phosphate</td>
<td>24729-96-2</td>
<td>246-433-0</td>
<td>Acute Tox.4 (H302)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Eye Irrit.2A (H319)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skin Irrit.3 (H316)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Skin Sens.1 (H317)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stearic acid</td>
<td>57-11-4</td>
<td>200-313-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hazardous</th>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Isostearyl Alcohol</td>
<td>27458-93-1</td>
<td>248-470-8</td>
<td>Not Listed</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Sodium Lauroylsarcosinate</td>
<td>137-16-6</td>
<td>205-281-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Potassium stearate</td>
<td>593-29-3</td>
<td>209-786-1</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Cetyl/Stearyl alcohol</td>
<td>67762-27-0</td>
<td>267-008-6</td>
<td>Not Listed</td>
<td>2.5</td>
</tr>
<tr>
<td></td>
<td>Methylparaben</td>
<td>99-76-3</td>
<td>202-785-7</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td>Water, purified</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed
5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture
Hazardous Combustion: Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters
During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up
Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Glycerin, USP
Australia TWA 10 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Lotion
Odor: No data available.
Molecular Formula: Mixture
Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.

Color: Colorless
Odor Threshold: No data available.
Molecular Weight: Mixture
9. PHYSICAL AND CHEMICAL PROPERTIES

Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Clindamycin Phosphate
No data available
Water, purified
No data available
Methylparaben
No data available
Cetyl/Stearyl alcohol
No data available
Glycerin, USP
No data available
Glyceryl stearate
No data available
Potassium stearate
No data available
Isostearyl Alcohol
No data available
Sodium Lauroylsarcosinate
No data available
Stearic acid
No data available
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable at normal conditions
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause mild skin irritation (based on animal data). An Occupational Exposure Limit has been established for one or more of the ingredients (see Section 8).

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused burning sensation of the skin, itching, abnormal redness of skin (erythema). Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

Acute Toxicity: (Species, Route, End Point, Dose)

<table>
<thead>
<tr>
<th>Material</th>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin Phosphate</td>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>1832 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Para-periosteal</td>
<td>LD 50</td>
<td>321 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Intraperitoneal</td>
<td>LD 50</td>
<td>745 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Oral</td>
<td>LD 50</td>
<td>2359 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Intravenous</td>
<td>LD 50</td>
<td>820 mg/kg</td>
</tr>
<tr>
<td>Glycerin, USP</td>
<td>Mouse</td>
<td>Oral</td>
<td>LD 50</td>
<td>4090 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>12.6 g/kg</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Dermal</td>
<td>LD 50</td>
<td>&gt; 10 g/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Inhalation</td>
<td>LC50 1hr</td>
<td>&gt; 570 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Dermal</td>
<td>LD 50</td>
<td>&gt; 21.9 g/kg</td>
</tr>
<tr>
<td>Glyceryl stearate</td>
<td>Rat</td>
<td>IP</td>
<td>LD50</td>
<td>200 mg/kg</td>
</tr>
<tr>
<td>Stearic acid</td>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>&gt; 4640 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Dermal</td>
<td>LD 50</td>
<td>&gt; 5000 mg/kg</td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

<table>
<thead>
<tr>
<th>Material</th>
<th>Study Type</th>
<th>Species</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindamycin Phosphate</td>
<td>Eye Irritation</td>
<td>Rabbit</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Skin Irritation</td>
<td>Rabbit</td>
<td>Mild</td>
</tr>
<tr>
<td>Glycerin, USP</td>
<td>Eye Irritation</td>
<td>Rabbit</td>
<td>Mild</td>
</tr>
<tr>
<td>Stearic acid</td>
<td>Skin Irritation</td>
<td>Rabbit</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Eye Irritation</td>
<td>Rabbit</td>
<td>Mild</td>
</tr>
</tbody>
</table>

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
11. TOXICOLOGICAL INFORMATION

Clindamycin Phosphate
6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose
6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system

Stearic acid
30 Week(s) Rat Oral 300 ppm LOAEL Adipose tissue

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate
Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic
Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic
Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic
Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity
Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate
Bacterial Mutagenicity (Ames) Salmonella Negative
In Vitro Micronucleus Rat Negative

Stearic acid
In Vitro Bacterial Mutagenicity (Ames) Salmonella Negative
Unscheduled DNA Synthesis E. coli Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Stearic acid
26 Week(s) Rat Subcutaneous 0.5 mg/kg/week NOAEL Not carcinogenic
52 Week(s) Mouse Subcutaneous 0.05 mg/kg/week LOAEL Tumors

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP
Onchorhyncus mykiss (Rainbow Trout) LC50 96 Hours 50 mg/L
Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

**Isostearyl Alcohol**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 248-470-8

**Sodium Lauroylsarcosinate**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 205-281-5

**Glycerin, USP**
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present

CLINDAMYCIN PHOSPHATE TOPICAL LOTION
15. REGULATORY INFORMATION

REACH - Annex V - Exemptions from the obligations of Register:
Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bio accumulative, and toxic or very persistent and very bio accumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern.

EU EINECS/ELINCS List
200-289-5

Potassium stearate
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 209-786-1

Glyceryl stearate
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 204-664-4

Cetyl/Stearyl alcohol
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 267-008-6

Clindamycin Phosphate
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
EU EINECS/ELINCS List 246-433-0

Methylparaben
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List 202-785-7

Water, purified
CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>EU EINECS/ELINCS List</th>
<th>231-791-2</th>
</tr>
</thead>
</table>

Stearic acid

| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 200-313-4 |

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation
Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date: 31-Jul-2018

Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet